Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 6—June 2007

Letter

Multidrug-Resistant Acinetobacter baumannii

Vladimir Krcmery*Comments to Author  and Erich Kalavsky†
Author affiliations: *St Elizabeth School of Health and Social Sciences, Bratislava, Slovakia; †Trnava University, Trnava, Slovakia

Main Article

Table

Risk factors and outcome for 27 neutropenic cancer patients with bacteremia due to multidrug-resistant (MDR) or drug-susceptible Acinetobacter baumannii infection

Characteristic All patients, no. (%)
(N = 27) Patients with drug-susceptible A. baumannii, no. (%)*
(n = 12, 44%) Patients with MDR
A. baumannii, no. (%)*
(n = 15, 56%)
Risk for bacteremia
Central venous catheter 19 (70.4) 9 (75.0) 10 (66.7)
Acute leukemia 11 (40.7) 6 (50.0) 5 (33.3)
Previous prophylaxis with quinolones 14 (51.9) 8 (66.7) 6 (40.0)
Previous therapeutic treatment with cephalosporins 15 (55.6) 8 (66.7) 7 (46.7)
Previous therapeutic treatment with carbapenems 8 (29.6) 4 (33.3) 4 (26.7)
Outcome
Septic shock 4 (14.8) 2 (16.7) 2 (13.3)
Death 2 (7.4) 1 (8.3) 1 (6.7)

*Insignificant difference between patients with drug-susceptible infection and those with MDR infection (p<0.05 by univariate analysis).

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO